Replies to post #106888 on Biotech Values

[DewDiligence]

MNTA 2010-2011 News Flow

[Removed entries for 3Q10 CC’s and added entry for
NVS’ 4Q10; updated timing for Copaxone patent trial.]


Lovenox

• 27-Jan-2011: NVS’ 4Q10 financial results and conference call, where NVS will report 4Q10 sales of generic Lovenox.


Copaxone

• Timing uncertain (but before start of Copaxone trial): District Court ruling on Markman (claims construction) hearing.

• 1H11: Start of trial on Copaxone patents. (Teva’s suit against NVS/MNTA has been consolidated with Teva’s suit against Mylan.)

• Timing uncertain: FDA feedback on Copaxone ANDA. MNTA would presumably disclose these details only if they were deemed to have a material affect on the probability or timing of eventual FDA approval.


M118

• Timing uncertain: M118 partnership followed by start of phase-2b trials. (Phase-2b trials in ACS are sufficiently large and expensive that MNTA will not conduct such trials without a partner.)


Other programs

• 1H11: IND filing for M402, MNTA’s proprietary heparin-based cancer drug, followed by the start of a phase-1 trial.

• Timing uncertain: One or more FoB partnerships.